What type of stem cells do you use for Parkinson’s Disease?
For Parkinson's disease, Stem Cell Mexico uses allogeneic mesenchymal stromal cells (MSCs) derived from Wharton's jelly, the connective tissue of donated umbilical cords, usually delivered by intravenous (IV) infusion as part of a supportive protocol.

These cells are not intended to replace the dopamine-producing neurons lost in Parkinson's. Instead, they are used for their anti-inflammatory, immunomodulatory and neurotrophic (nerve-supporting) signals, which may help create a healthier environment for the brain. This is a different strategy from the dopamine cell replacement therapies being tested in neurosurgical clinical trials, which use neurons grown from pluripotent stem cells.
Knowing which cell type is used, and why, is essential for understanding what a treatment can and cannot do. This guide explains the options and the evidence behind them.
Why the type of cell matters so much in Parkinson's
Parkinson's disease involves the gradual loss of dopamine-producing neurons in a region called the substantia nigra, along with the accumulation of a misfolded protein (alpha-synuclein) and chronic inflammation in the brain. Different cell therapies target different parts of this process:
- Replacing dopamine neurons to restore dopamine where it is missing.
- Protecting remaining neurons and slowing damage by reducing inflammation and oxidative stress.
- Supporting brain repair through growth factors that promote neuron survival and connections.
No single cell type does all of these things. The choice of cell defines the goal of treatment.
Why inflammation is a target in Parkinson's
For many years, Parkinson's was seen purely as a problem of dying dopamine neurons. Research now shows that inflammation plays an active role. Brain immune cells called microglia become persistently activated in Parkinson's, releasing inflammatory molecules that can damage neighboring neurons. Signs of inflammation also appear in the blood and even in the gut, where some researchers believe the disease process may begin in certain people. This growing understanding is one of the main reasons MSCs are being studied: their best-documented effects are calming excessive immune activity and releasing protective growth factors. If inflammation contributes to the progression of neuron loss, reducing it could, in theory, help protect the neurons that remain. This hypothesis is being tested in clinical studies.
The main cell types studied in Parkinson's
1. Pluripotent stem cell-derived dopamine neurons (ESC or iPSC)
Scientists grow dopamine neuron precursors from embryonic stem cells or induced pluripotent stem cells and implant them surgically into the putamen, the brain area that needs dopamine. In 2025, Nature published a phase 1 trial (Tabar and colleagues) in which 12 patients received cells derived from embryonic stem cells. The trial met its safety goals, imaging showed the grafts survived, and the higher-dose group had substantial improvements in motor scores measured off medication. A parallel trial from Japan used induced pluripotent stem cells with encouraging early results. This is a true cell replacement strategy, but it requires neurosurgery and is currently available only in clinical trials.
2. Mesenchymal stromal cells (MSCs)
MSCs from bone marrow, fat or umbilical cord do not become functional dopamine neurons in meaningful numbers. Their potential lies in their secretions: growth factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and hepatocyte growth factor (HGF), anti-inflammatory molecules and extracellular vesicles. They are usually given intravenously, which avoids brain surgery. This is the approach used at Stem Cell Mexico.
3. Fetal tissue transplants
Decades ago, researchers transplanted fetal brain tissue into patients with Parkinson's. Results were mixed, and some patients developed troublesome involuntary movements. This approach informed today's research but is not used in routine care.
4. Hematopoietic stem cells
Blood-forming stem cells are not used to treat Parkinson's disease.
Why Wharton's jelly MSCs
Within the MSC family, Stem Cell Mexico uses cells from Wharton's jelly for several reasons:
- Neurotrophic profile: a comparative study in Scientific Reports (Petrenko and colleagues, 2020) found that Wharton's jelly MSCs secreted higher levels of BDNF, NGF, HGF and fibroblast growth factor 2 than bone marrow MSCs, and that MSCs from all sources tested could stimulate nerve fiber growth in the laboratory.
- Young, healthy source: cells from newborn tissue avoid the age-related decline seen in cells from older adults, which matters because most people with Parkinson's are over 60.
- No harvesting procedure: patients do not need bone marrow aspiration or liposuction.
- Defined dose and documentation: cells are expanded in a licensed laboratory, tested and documented before release.
- No donor matching required: MSCs have low immunogenicity, although they are not entirely invisible to the immune system.
How the cells are given
For Parkinson's protocols, cells are typically administered by IV infusion, which is minimally invasive and allows systemic effects on inflammation and immune activity. After IV infusion, many MSCs are temporarily filtered by the lungs, and their effects on the brain are thought to occur largely through circulating signals and the immune system rather than through large numbers of cells reaching the brain directly. Researchers continue to study whether other routes, doses or repeated infusions improve results.
What the evidence says for MSCs in Parkinson's
A phase 1 trial published in Movement Disorders (Schiess and colleagues, 2021) gave single IV infusions of allogeneic bone-marrow-derived MSCs at increasing doses to people with mild to moderate Parkinson's disease. The treatment was safe and well tolerated, with no serious adverse events attributed to the cells, and exploratory measures suggested possible improvements and reduced inflammatory markers at the highest dose. The same group has continued with a randomized trial to study efficacy more rigorously.
Overall, evidence for MSCs in Parkinson's shows:
- Established: a favorable short-term safety profile with IV administration.
- Growing: biological plausibility and signals of benefit.
- What it is not designed to do: replace standard Parkinson's treatment or stop disease progression.
It is important not to apply results from surgical dopamine neuron transplants to MSC infusions, or vice versa. They are different therapies with different goals.
Regulatory context
No stem cell therapy is approved by the FDA or the European Medicines Agency for Parkinson's disease. In Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS.
What this means for you
If you are considering MSC therapy for Parkinson's, it is reasonable to see it as a supportive approach that may help some patients with symptoms such as stiffness, energy or overall well-being, alongside standard care. It is not a replacement for dopamine medications, deep brain stimulation when indicated, or exercise and rehabilitation, which remain the strongest tools for maintaining function. If your main goal is restoring dopamine production, cell replacement trials are the relevant field to follow, and your neurologist can advise you about eligibility.
Who may be a candidate for MSC therapy
- A confirmed diagnosis of Parkinson's disease (not atypical parkinsonism).
- Stable general health and blood pressure, without active infection.
- No cancer history within the past five years.
- Ongoing care with a neurologist and realistic, measurable goals.
How results are evaluated
Changes, if they occur, are typically assessed over two to six months using standardized scales such as the MDS-UPDRS, timed walking tests, symptom diaries and your neurologist's observations. Recording a baseline before treatment, including videos of walking and tremor, makes comparison much more reliable. It is also helpful to keep a simple daily diary for two weeks before and after treatment, noting on and off periods, sleep quality, energy and any falls.
Preparing for treatment
Bring a complete list of your medications with exact dosing times, because levodopa and other Parkinson's drugs should be taken on schedule throughout your trip and treatment day; do not stop them unless your neurologist instructs you to. Share recent neurology notes and any imaging. Tell the team about dizziness on standing, swallowing difficulties, hallucinations, sleep problems or falls, so they can plan safe transfers, meals and monitoring. Arriving a day early and keeping the schedule calm helps many patients manage fatigue and "off" periods during travel.
Risks and limitations
IV MSC infusions are generally well tolerated. Possible effects include temporary fever, headache or fatigue, and rare risks include allergic reactions or thrombotic events. Patients with low blood pressure on standing or a high fall risk need extra care during travel and treatment. Results vary between patients.
Questions to ask during your evaluation
- Is this treatment intended to replace dopamine neurons or to support the brain environment?
- Why are Wharton's jelly MSCs chosen for my case?
- What dose and route will be used?
- How will we measure change, and how will you coordinate with my neurologist?
- What documentation will I receive about the cells?
Bottom line
For Parkinson's disease, Stem Cell Mexico uses allogeneic Wharton's jelly MSCs, usually by IV infusion and, in selected cases after reviewing your medical reports, by intrathecal application, as a supportive approach based on their anti-inflammatory and neurotrophic properties. This is distinct from surgical dopamine neuron replacement, which is advancing in clinical trials. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your symptoms, goals and medical history.
References
- Tabar V et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson's disease. Nature, 2025 (opens in a new tab)
- Schiess M et al. Allogeneic bone marrow-derived mesenchymal stem cell safety in idiopathic Parkinson's disease. Movement Disorders, 2021 (opens in a new tab)
- Petrenko Y et al. A comparative analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential. Scientific Reports, 2020 (opens in a new tab)
